Medicxi — 2019 Investments

1 investments dated 2019 · listed companies and verified rows first · show all

Phathom Pharmaceuticalsphathompharma.com in 𝕏May 2019 · $90M

Phathom Pharmaceuticals is a pharmaceutical company that develops and markets prescription treatments, including VOQUEZNA (vonoprazan) for gastrointestinal conditions, in the U.S. market.

BiotechHealthtech

Mr. Basta(CEO)

Co-investorsCatalys Pacific Frazier Life Sciences New Enterprise Associates (NEA)Astellas Venture Management LLC

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.